USPTO serial 86034690
KANNALIFE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOOK, JEFFREY J
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KANNALIFE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brad M. Behar
Brad M. Behar Brad M. Behar & Associates, PLLC94 Second StreetMineola, NY 11501UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Active chemical ingredients for use in the manufacture of pharmaceuticals for treating Oxidative Stress Related and Neurodegenerative Diseases; Chemical additives for use in the manufacture of naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Emollient used as an ingredient in the manufacture of cosmetics, toiletries, and pharmaceuticals | ACTIVE | — |
| 005 | Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Homeopathic pharmaceuticals for use in the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Inhalers filled with naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents for epidermis; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations for the treatment and prevention of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical preparations, namely, elixirs for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, psychotropics; Plant extracts for medical, veterinary and pharmaceutical purposes; Sunburn preparations for pharmaceutical purposes; Syringes sold filled with naturopathic and/or pharmaceutical products for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Syrups for pharmaceutical purposes for the treatment of Oxidative Stress Related and Neurodegenerative Diseases; Therapeutic pharmaceutical for the treatment of Oxidative Stress Related and Neurodegenerative Diseases | ACTIVE | — |
| 042 | Conducting early evaluations in the field of new pharmaceuticals; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Development of pharmaceutical preparations and medicines; Laboratory research services relating to pharmaceuticals; Pharmaceutical products development; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research in the field of Oxidative Stress Related and Neurodegenerative Diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by KannaLife Sciences, Inc.
- Other trademarks owned by KannaLife Sciences, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named KANNALIFE
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 11, 2015 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 11, 2015 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 7, 2014 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 13, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 12, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 12, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 11, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 23, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 8, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jul 7, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 10, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 10, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 4, 2014 | ALIE | ASSIGNED TO LIE | — |
| May 21, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 27, 2013 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2013 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 21, 2013 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Aug 20, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 15, 2013 | NWAP | NEW APPLICATION ENTERED | — |